Skip to main content

Advertisement

SpringerLink
Log in

Conversion surgery for initially unresectable advanced biliary tract cancer treated with gemcitabine plus cisplatin combination chemotherapy: a case report and literature review

  • Case report
  • Published:
International Cancer Conference Journal Aims and scope Submit manuscript

Abstract

Recently, the number of reports describing patients with initially unresectable biliary tract cancer (BTC) who underwent resection in the form of conversion surgery is increasing. Gemcitabine plus cisplatin (GC) combination therapy has been reported to significantly prolong the median survival time from 8.1 to 11.7 months compared with conventional gemcitabine therapy in patients with unresectable BTC. We report the case of a patient with unresectable BTC who underwent conversion surgery with a partial response to GC combination therapy. A 78-year-old woman was diagnosed with unresectable BTC with invasion of the right hepatic artery by lymph node metastasis and liver metastases. The patient received GC combination therapy. After 6 cycles of chemotherapy, the patient achieved a partial response. The radiological findings revealed a marked shrinkage in the primary lesion and the disappearance of lymph node and liver metastases. Therefore, the patient underwent conversion surgery, including biliary tract resection and regional lymph node dissection. For postoperative follow-up, the patient was monitored without receiving adjuvant chemotherapy. The patient had not exhibited recurrence during the 12-month follow-up period. We report the case of a patient with unresectable BTC who underwent conversion surgery with a partial response to GC combination therapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price includes VAT (France)

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7
Fig. 8

References

  1. Randi G, Malvezzi M, Levi F et al (2009) Epidemiology of biliary tract cancers: an update. Ann Oncol 20:146–159

    Article  CAS  Google Scholar 

  2. Hori M, Matsuda T, Shibata A et al (2015) Cancer incidence and incidence rates in Japan in 2009: a study of 32 population-based cancer registries for the Monitoring of Cancer Incidence in Japan (MCIJ) project. Jpn J Clin Oncol 45:884–891

    Article  Google Scholar 

  3. Valle J, Wasan H, Palmer DH et al (2010) Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med 362:1273–1281

    Article  CAS  Google Scholar 

  4. Morizane C, Okusaka T, Mizusawa J et al (2019) Combination gemcitabine plus S-1 versus gemcitabine plus cisplatin for advanced/recurrent biliary tract cancer: the FUGA-BT (JCOG1113) randomized phase III clinical trial. Ann Oncol 30:1950–1958

    Article  CAS  Google Scholar 

  5. Sakai D, Kanai M, Kobayashi S et al (2018) Randomized phase III study of gemcitabine, cisplatin plus S-1 (GCS) versus gemcitabine, cisplatin (GC) for advanced biliary tract cancer (KHBO1401-MITSUBA). Ann Oncol 29:viii205–viii270

    Article  Google Scholar 

  6. Kato A, Shimizu H, Ohtsuka M et al (2013) Surgical resection after downsizing chemotherapy for initially unresectable locally advanced biliary tract cancer: a retrospective single-center study. Ann Surg Oncol 20:318–324

    Article  Google Scholar 

  7. Kato A, Shimizu H, Ohtsuka M et al (2015) Downsizing chemotherapy for initially unresectable locally advanced biliary tract cancer patients treated with gemcitabine plus cisplatin combination therapy followed by radical surgery. Ann Surg Oncol 22:S1093–S1099

    Article  Google Scholar 

  8. Evans DB, Rich TA, Byrd DR et al (1992) Preoperative chemoradiation and pancreaticoduodenectomy for adenocarcinoma of the pancreas. Arch Surg 127:1335–1339

    Article  CAS  Google Scholar 

  9. Satoi S, Yamaue H, Kato K et al (2013) Role of adjuvant surgery for patients with initially unresectable pancreatic cancer with a long-term favorable response to non-surgical anti-cancer treatments: results of a project study for pancreatic surgery by the Japanese Society of Hepato-Biliary-Pancreatic Surgery. J Hepatobiliary Pancreat Sci 20:590–600

    Article  Google Scholar 

  10. Adam R, Wicherts DA, de Haas RJ et al (2009) Patients with initially unresectable colorectal liver metastases: is there a possibility of cure? J Clin Oncol 27:1829–1835

    Article  Google Scholar 

  11. Bismuth H, Adam R, Levi F et al (1996) Resection of nonresectable liver metastases from colorectal cancer after neoadjuvant chemotherapy. Ann Surg 224:509–520

    Article  CAS  Google Scholar 

  12. Rayar M, Sulpice L, Edeline J et al (2015) Intra-arterial yttrium-90 radioembolization combined with systemic chemotherapy is a promising method for downstaging unresectable huge intrahepatic cholangiocarcinoma to surgical treatment. Ann Surg Oncol 22:3102–3108

    Article  CAS  Google Scholar 

  13. Agrawal S, Mohan L, Mourya C et al (2016) Radiological downstaging with neoadjuvant therapy in unresectable gall bladder cancer cases. Asian Pac J Cancer Prev 17:2137–2140

    Article  Google Scholar 

  14. Engineer R, Goel M, Chopra S et al (2016) Neoadjuvant chemoradiation followed by surgery for locally advanced gallbladder cancers: a new paradigm. Ann Surg Oncol 23:3009–3015

    Article  Google Scholar 

  15. Konstantinidis IT, Groot Koerkamp B, Do RK et al (2016) Unresectable intrahepatic cholangiocarcinoma: Systemic plus hepatic arterial infusion chemotherapy is associated with longer survival in comparison with systemic chemotherapy alone. Cancer 122:758–765

    Article  Google Scholar 

  16. Creasy JM, Goldman DA, Dudeja V et al (2016) Systemic chemotherapy combined with resection for locally advanced gallbladder carcinoma: surgical and survival outcomes. J Am Coll Surg 224:906–916

    Article  Google Scholar 

  17. Sumiyoshi T, Shima Y, Okabayashi T et al (2018) Chemoradiotherapy for initially unresectable locally advanced cholangiocarcinoma. World J Surg 42:2910–2918

    Article  Google Scholar 

  18. Le Roy B, Gelli M, Pittau G et al (2018) Neoadjuvant chemotherapy for initially unresectable intrahepatic cholangiocarcinoma. Br J Surg 105:839–847

    Article  Google Scholar 

  19. Suzuki Y, Kan M, Kimura G et al (2019) Predictive factors of the treatment outcome in patients with advanced biliary tract cancer receiving gemcitabine plus cisplatin as first-line chemotherapy. J Gastroenterol 54:281–290

    Article  CAS  Google Scholar 

  20. Noji T, Nagayama M, Imai K et al (2020) Conversion surgery for initially unresectable biliary malignancies: a multicenter retrospective cohort study. Surg Today 50:1409–1417

    Article  Google Scholar 

  21. Kobayashi S, Ueno M, Ohkawa S et al (2012) A retrospective study of S-1 monotherapy as second-line treatment for patients with advanced biliary tract cancer. Jpn J Clin Oncol 42:800–806

    Article  Google Scholar 

  22. Robinson K, Lambiase L, Li J et al (2003) Fatal cholestatic liver failure associated with gemcitabine therapy. Dig Dis Sci 48:1804–1808

    Article  Google Scholar 

  23. Primrose JN, Fox RP, Palmer DH et al (2019) Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study. Lancet Oncol 20:663–673

    Article  CAS  Google Scholar 

  24. Nakachi K, Konishi M, Ikeda M et al (2018) A randomized Phase III trial of adjuvant S-1 therapy vs observation alone in resected biliary tract cancer: Japan Clinical Oncology Group Study (JCOG1202, ASCOT). Jpn J Clin Oncol. https://doi.org/10.1093/jjco/hyy004

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

We thank the Department of Pathology, Saitama Cancer Center, for consulting on the histopathological findings.

Funding

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Author information

Authors and Affiliations

  1. Department of Gastroenterological Surgery, Saitama Cancer Center, 780 Komuro, Ina-machi, Kita-Adachi-gun, Saitama, 362-0806, Japan

    Ryoichi Miyamoto, Toshiro Ogura, Amane Takahashi, Hiroyuki Ishida, Shinichi Matsudaira, Katsumi Amikura & Yoshiyuki Kawashima

  2. Department of Gastroenterology, Saitama Cancer Center, Kita-Adachi-gun, Saitama, Japan

    Yuko Suzuki & Satoshi Shimizu

  3. Department of Pathology, Jichi Medical University, Tochigi, Japan

    Atsushi Kihara

  4. Department of Pathology, Saitama Cancer Center, Kita-Adachi-gun, Saitama, Japan

    Hiroaki Kanda

Authors
  1. Ryoichi Miyamoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Toshiro Ogura
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Amane Takahashi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Hiroyuki Ishida
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Shinichi Matsudaira
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Katsumi Amikura
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Yuko Suzuki
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Satoshi Shimizu
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Atsushi Kihara
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Hiroaki Kanda
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Yoshiyuki Kawashima
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

All authors participated in the treatment of this patient. All authors read and approved the final manuscript.

Corresponding author

Correspondence to Ryoichi Miyamoto.

Ethics declarations

Conflict of interest

There are no potential conflicts of interest to disclose.

Informed consent

Written informed consent was obtained from the patient for publication of this case report and accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal on request.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Miyamoto, R., Ogura, T., Takahashi, A. et al. Conversion surgery for initially unresectable advanced biliary tract cancer treated with gemcitabine plus cisplatin combination chemotherapy: a case report and literature review. Int Canc Conf J 11, 188–195 (2022). https://doi.org/10.1007/s13691-022-00545-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13691-022-00545-y

Keywords

Search

Navigation